公开(公告)号：US20220381796A1

公开(公告)日：2022-12-01

申请号：US17747397

申请日：2022-05-18

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: G01N33/68

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a pediatric subject for traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a pediatric subject would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP, UCH-L1 or GFAP and UCH-L1.

公开(公告)号：US20210302441A1

公开(公告)日：2021-09-30

申请号：US17224685

申请日：2021-04-07

Applicant: Abbott Laboratories ,  Cedars-Sinai Medical Center

Inventor： Jennifer Van Eyk ,  Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Vidya Venkatraman ,  Shenyan Zhang

IPC: G01N33/68

Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.

公开(公告)号：US20210088533A1

公开(公告)日：2021-03-25

申请号：US17099668

申请日：2020-11-16

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Jaime Marino ,  Raj Chandran ,  Tianming Zhang ,  Saul Datwyler

IPC: G01N33/68 ,  A61B5/00 ,  A61B5/055

Abstract: Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MM) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US09713598B2

公开(公告)日：2017-07-25

申请号：US14775972

申请日：2014-03-14

Applicant: ABBOTT LABORATORIES

Inventor： Menghua Luo ,  Suzette Pereira ,  Neile Edens ,  Gerard Davis ,  Susan Gawel ,  Raj Chandran

IPC: A61K31/19 ,  G01N33/68

CPC classification number: A61K31/19 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/4704 ,  G01N2333/575 ,  G01N2800/52

Abstract: Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future.

公开(公告)号：US20250020665A1

公开(公告)日：2025-01-16

申请号：US18792630

申请日：2024-08-02

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Jaime Marino ,  Raj Chandran ,  Tianming Zhang ,  Saul Datwyler

IPC: G01N33/68 ,  A61B5/00 ,  A61B5/055 ,  A61B6/03 ,  A61B6/50

Abstract: Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MRI) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20250003988A1

公开(公告)日：2025-01-02

申请号：US18443416

申请日：2024-02-16

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino ,  Hongwei Zhang

IPC: G01N33/68

Abstract: Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.

公开(公告)号：US20240426842A1

公开(公告)日：2024-12-26

申请号：US18640030

申请日：2024-04-19

Applicant: Abbott Laboratories ,  Cedars-Sinai Medical Center

Inventor： Jennifer Van Eyk ,  Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Vidya Venkatraman ,  Shenyan Zhang

IPC: G01N33/68

Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.

公开(公告)号：US20240337668A1

公开(公告)日：2024-10-10

申请号：US18632426

申请日：2024-04-11

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2333/435 ,  G01N2333/948 ,  G01N2800/28

Abstract: Disclosed herein are methods that aid in the determination of whether a subject has or may have sustained an acquired brain injury, such as a traumatic brain injury (TBI), by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in one or more samples taken from a subject, such as a human subject.

公开(公告)号：US20240110928A1

公开(公告)日：2024-04-04

申请号：US18474826

申请日：2023-09-26

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/916 ,  G01N2800/28 ,  G01N2800/56

Abstract: Disclosed herein are methods for aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild or a supermild traumatic brain injury.

公开(公告)号：US20230213536A1

公开(公告)日：2023-07-06

申请号：US18147094

申请日：2022-12-28

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/56 ,  G01N2800/28

Abstract: Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.